Compare ONTF & AKBA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ONTF | AKBA |
|---|---|---|
| Founded | 1998 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 347.2M | 375.0M |
| IPO Year | 2021 | 2014 |
| Metric | ONTF | AKBA |
|---|---|---|
| Price | $8.11 | $1.16 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 3 |
| Target Price | ★ $8.10 | $4.67 |
| AVG Volume (30 Days) | 986.7K | ★ 2.7M |
| Earning Date | 05-06-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 32.67 | ★ 93.94 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $139,312,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $1.51 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $4.70 | $1.13 |
| 52 Week High | $8.11 | $4.08 |
| Indicator | ONTF | AKBA |
|---|---|---|
| Relative Strength Index (RSI) | 67.87 | 34.82 |
| Support Level | $7.84 | $1.16 |
| Resistance Level | N/A | $1.56 |
| Average True Range (ATR) | 0.02 | 0.07 |
| MACD | -0.01 | -0.03 |
| Stochastic Oscillator | 88.89 | 12.05 |
ON24 Inc provides a cloud-based intelligent engagement platform that combines experiences with personalization and content, to enable sales and marketing organizations to capture and act on connected insights at scale. The company's platform offers a portfolio of interactive and hyper-personalized digital experience products that create and capture actionable, real-time data at scale from millions of professionals to provide businesses with buying signals and behavioral insights to efficiently convert prospects into customers. It provides solutions to Financial services, Life Sciences, Life sciences, Insurance, Technology, Associations, and Others. Geographically, the company derives maximum revenue from United States, and also has its presence in EMEA and Other Countries.
Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, and HIF-PH inhibitors in preclinical development.